In this issue of the *Journal,* Choudry et al. ([@bib1]) present a single-center experience with primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) during the coronavirus disease-2019 (COVID-19) pandemic. STEMI registries during the COVID-19 pandemic are a rainbow of unique colors. The London experience with primary PCI focused a narrow lens onto COVID-19 STEMI to ask an important question: for patients with an acute culprit lesion, are there unique features of the PCI procedure that warrant caution and concern? Via detailed angiographic comparison to a COVID-19--negative control group, they observed a dramatic increase in thrombus burden that may compliment prior insights into the pathophysiology of the COVID-19 pandemic.

The Rainbow of COVID-19 STEMI Registries {#sec1}
========================================

The inclusion criteria of COVID-19 STEMI registries vary widely: some include COVID-19--positive patients, some do not. And, the pathophysiology in COVID-19 STEMI registries represent a spectrum of disease from a typical coronary culprit plaque requiring primary PCI to nonobstructive coronary artery disease with type II myocardial infarction or myocarditis. This rainbow-like spectrum of COVID-19--related STEMI registries is exemplified by looking at 4 recent examples spanning the globe ([@bib1], [@bib2], [@bib3], [@bib4]) ([Table 1](#tbl1){ref-type="table"} ).Table 14 Registries of Primary PCI During the COVID-19 PandemicRegistry CharacteristicsLondon, England (N = 115) ([@bib1])Lombardy, Italy (N = 28) ([@bib2])New York City, United States (N = 18) ([@bib3])Hong Kong, China (N = 125) ([@bib4])Study design2 arms concurrent comparison, single centerSingle arm multicenterSingle arm multicenter2 arms, historical comparison, single centerPatient populationCOVID-19 positive primary PCI (n = 39)\
COVID-19 negative primary PCI (n = 76)Consecutive COVID-19 positive patients with STEMI undergoing coronary angiographyConsecutive COVID-19 positive patients with STEMIPrimary PCI patients during the COVID-19 pandemic (n = 7)\
Primary PCI patients during 2018--2019 (n = 108)\
All COVID-19 negativeSTEMI without obstructive CADNoneYes, n = 11 (39.3% of the cohort)Yes, ≥50% of the cohort (not all patients had angiography)NoneMechanical ventilationCOVID+: 12.8%\
COVID−: 6.6%Not reportedTotal: 67% myocardial infarction: 62%\
myocardial injury, no CAD: 70%Not reportedDelay in STEMI reperfusion timesNo delay for both groupsNot reportedNot reportedYes, all intervals marked prolongation of symptom onset to device timeHospital mortalityCOVID-19 positive: 17.9%\
COVID-19 negative: 6.5% (p = 0.10)Total: 39.3%\
No culprit lesion: 45.5%\
Culprit lesion: 35.3%Total: 72%\
Myocardial infarction: 50%\
Myocardial injury, no CAD: 90%Not reportedKey observationLarge thrombus burden:\
COVID-19 +: 75.0%\
COVID-19 −: 31.4% (p = 0.0006)COVID-19 patients may present with STEMI: nearly 40% have no culprit lesionCOVID-19 patients with STEMI have variable pathophysiology: ≥50% of patients have no culprit lesionSTEMI systems of care are impacted by the COVID-19 pandemic[^2]

The Hong Kong experience during the COVID-19 pandemic (N = 125) provided insights into delays in STEMI presentation ([@bib4]). The authors observed a prolongation of symptom onset to first medical contact (as well as door-to-device) time intervals compared with a historical control period; the observation of delayed or decreased STEMI patient presentations correlated with other STEMI registries, suggesting that patients avoided emergency room evaluation during the pandemic ([@bib5],[@bib6]). Only 7 patients in the sample underwent primary PCI during the COVID-19 pandemic (compared with 118 primary PCI patients in the non--COVID-19 historic control groups) and none of the patients were COVID-19 positive. The insights from New York City (N = 18) and Lombardy Italy (N = 28) are completely different: 1) \>40% of COVID-19--positive patients with ST-segment elevations do not actually have a thrombotic culprit coronary artery lesion; and 2) STEMI mortality rates in COVID-19--positive patients are high (39% in Lombardy, 72% in New York) ([@bib2],[@bib3]).

The London group brings a new color to the spectrum of COVID-19 STEMI registries. This study included both COVID-19--positive patients and a concurrent control group of COVID-19--negative patients presenting with STEMI (diagnosed by nasal swab or convincing radiological findings/symptoms immediately after PCI). This study is unique in exploring a single manifestation of COVID-19--related STEMI: patients who demonstrated a culprit lesion requiring immediate PCI. The simplest conclusion from this focused lens on COVID-19--related STEMI is that primary PCI is technically more complicated in the setting of acute coronavirus infection. The complexity is centered upon the unique burden of coronary thrombus ([Table 1](#tbl1){ref-type="table"}):•Large thrombus burden (modified thrombus grade 4/5) is twice as likely in patients with COVID-19 and STEMI compared with those without COVID-19 (75.0% vs. 31.4%; p = 0.0006).•Multivessel thrombosis was seen in 17.9% of COVID-19 STEMI patients compared with none of the COVID-19--negative patients, as seen in a prior case report ([@bib7]); stent thrombosis as the initial presentation was also 10 times more likely (p \< 0.05 for both comparisons).•Angiographic complexity led operators to enhanced use of glycoprotein IIb/IIIa inhibitors and thrombectomy to manage these challenging lesion characteristics.

Outcomes for COVID-19--positive patients described in the London registry elicits insight, opportunities, and challenges for primary PCI programs during the pandemic. Importantly, unlike the cohort undergoing primary PCI in Hong Kong ([@bib4]), median door to device times are not prolonged for either the COVID-19--positive or --negative patients (approximately 50 min in both groups). Second, unlike the New York and Lombardy experiences ([@bib2],[@bib3]), hospital mortality for COVID-19--positive STEMI patients was not in the 40% to 75% range; hospital mortality was nonsignificantly higher than in the COVID-19--negative group (17.9% COVID-19 positive vs. 6.5% COVID-19 negative; p = 0.10), but mortality rates were reasonable given that approximately one-fourth of the COVID-19--positive patients experienced a cardiac arrest. Prior studies of primary PCI have demonstrated increased mortality among patients with large thrombus burden ([@bib8]): larger sample sizes and longer-term follow-up of COVID-19--positive primary PCI patients are needed to confirm the interaction of coronavirus, large thrombus burden, and death.

Surrogate endpoints of reperfusion in this registry suggest that such a COVID-19--related clinical risk will be demonstrated in larger studies. For example, final myocardial blush grades of 2 to 3 were achieved in only 53.8% of COVID-19--positive primary PCI patients (compared with 93.3% of COVID-19--negative primary PCI patients; p \< 0.001), a surrogate endpoint that has previously correlated with clinical outcomes ([@bib9]). Thus, the London experience with reasonable time-based parameters and outcomes supports proposals recommending efficient primary PCI programs as the routine strategy for STEMI patients during the COVID-19 pandemic ([@bib10]); at the same time, the findings of a potential mortality and myocardial reperfusion risk provide an impetus to understand the pathophysiology that makes primary PCI more complex and higher-risk for COVID-19--positive STEMI patients.

COVID-19 and the Burden of Thrombus {#sec2}
===================================

Three-quarters of COVID-19--positive STEMI patients have a large coronary thrombus burden: can this finding compliment prior observations on the pathophysiology of COVID-19 infection? A marked inflammatory reaction occurs in the setting of COVID-19 infection ([@bib11]): this inflammatory response to the virus can be measured by multiple serological parameters including C-reactive protein and D-dimer ([@bib12]). The connection between inflammation and thrombosis is previously established and occurs via activation of leukocytes, platelets, endothelium, and smooth muscle cells ([@bib13]). Furthermore, the association of viral infection and enhanced risk of myocardial infarction has been described with respect to influenza, and an inflammatory mediation of risk is plausible ([@bib14],[@bib15]).

Does COVID-19 elicit a particularly intense inflammatory response that triggers thrombosis across multiple vascular beds, with STEMI-related large thrombus burden being 1 of many potential manifestations? A generalized hypercoagulability among critically ill COVID-19 patients has been demonstrated using thromboelastography ([@bib16]). Clinical manifestations of an inflammation-thrombosis-hypercoagulability cascade are supported by registries identifying an increased risk of deep vein thrombosis, pulmonary embolism, disseminated intravascular coagulation, and stroke among patients with COVID-19 ([@bib12]). Although increased risk of myocardial infarction with viral infection is previously described ([@bib14]), COVID-19 may be a special viral infection: for example, a comparison of ischemic stroke rates among patients with COVID-19 compared with patients with influenza infection noted a strikingly increased rate of ischemic stroke associated with COVID-19 (odds ratio: 7.6; 95% confidence interval: 2.3 to 25.2) ([@bib17]).

None of these registry associations can prove causality for a coronavirus-inflammation-thrombosis--mediated mechanism of STEMI or other ischemic events. But, the current London coronary thrombus data supports a fundamental hypothesis regarding the pathophysiology of COVID-19: coronavirus may induce an intense inflammatory reaction that manifests as thrombotic events across a broad spectrum of vascular beds. This conclusion may have therapeutic implications, including a potential role for enhanced anticoagulation strategies among patients critically ill with COVID-19 ([@bib18]). To demonstrate a potential link among COVID-19, thrombosis, and inflammation, the authors examined the association of modified thrombus grade and myocardial blush grade with D-dimer blood levels: the significant correlation is supportive of the inflammation-triggered mechanism. But, the overall correlation is still fairly weak (r \< 0.50 for both correlations with D-dimer). Thus, the current registry study is neither mechanistic nor definitive: enhanced tools like optical coherence tomography could provide insight into underlying coronary plaque pathophysiology.

The authors are to be congratulated for their observations during the pandemic: they have performed a unique registry of COVID-19--positive STEMI patients with a concurrent COVID-19--negative control group and provided insight into the feasibility and challenges of primary PCI. Their detailed analysis of angiographic data supports a broader hypothesis: patients with COVID-19 infection are at a specially enhanced risk of inflammation-triggered thrombus burden. These results need to be confirmed in a larger, multicenter registry with an adequate control group. And, if confirmed, the next step is both obvious and challenging: how will we prevent and optimally treat the thrombus-generating pathophysiology that appears to be fundamental to COVID-19 infection?
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[^1]: Editorials published in the *Journal of the American College of Cardiology* reflect the views of the authors and do not necessarily represent the views of *JACC* or the American College of Cardiology.

[^2]: CAD = coronary artery disease; COVID-19 = coronavirus disease-2019; PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction.
